Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014', provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Overview 6
Therapeutics Development 7
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Overview 7
Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Comparative Analysis 8
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics under Development by Companies 9
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Products under Development by Companies 12
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Companies Involved in Therapeutics Development 13
Lentigen Corporation 13
Shire Plc 14
Green Cross Corporation 15
JCR Pharmaceuticals Co., Ltd. 16
Fate Therapeutics, Inc. 17
biOasis Technologies Inc. 18
ArmaGen Technologies, Inc. 19
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
idursulfase - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
idursulfase - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
FT-1050 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
JR-032 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AGT-182 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
LG-1041 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Recombinant Enzyme to Replace Iduronate-2-Sulfatase for Hunter Syndrome - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Recent Pipeline Updates 36
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Dormant Projects 39
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Product Development Milestones 40
Featured News & Press Releases 40
Sep 18, 2014: biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation 40
Jun 17, 2014: ArmaGen Receives Notice of Allowance for U.S. Patent Covering Novel Investigational Therapy for Hunter Syndrome 41
Jul 18, 2013: ARMAGEN Receives US Orphan Designation For Lead Product AGT-182 41
Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press 42
Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome 43
Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase 43
Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), H2 2014 7
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Lentigen Corporation, H2 2014 13
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Shire Plc, H2 2014 14
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Green Cross Corporation, H2 2014 15
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2014 16
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by Fate Therapeutics, Inc., H2 2014 17
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by biOasis Technologies Inc., H2 2014 18
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline by ArmaGen Technologies, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics - Recent Pipeline Updates, H2 2014 36
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Dormant Projects, H2 2014 39